A pproximately one-quarter of people with stroke will suffer recurrence within a 4-year period.
Young and colleagues, 11 in this issue of Circulation, report a post hoc analysis of heart failure in the IRIS trial. No excess of heart failure serious adverse events with pioglitazone was reported in IRIS, but there was an increase in ankle edema. In this more granular analysis of heart failure outcomes, Young and colleagues 11 explored whether certain people were more at risk of pioglitazone-associated heart failure. They confirmed no overall excess of any confirmed heart failure, hospitalized heart failure, or nonhospitalized heart failure with pioglitazone. This finding was consistent across 7 individual heart failure risk factors and across the range of a combined heart failure risk score. One treatment interaction was significant: pioglitazone treatment was associated with increased risk of heart failure in people with a baseline HbA1c level of 6.5% to 6.9%, although the effect estimate lacked precision. It is important to note that this level of HbA1c would now denote diabetes mellitus but did not at the start of the IRIS trial. This finding is consistent with a subgroup analysis of people with previous stroke in the PROactive trial (PROspective Pioglitazone Clinical Trial in Macrovascular Events). 12 This trial demonstrated a reduction in total recurrent stroke with pioglitazone, and although there was no sta-tistically significant difference, the rate of heart failure requiring hospitalization was ≈50% higher (6.4% with pioglitazone compared with 4% with placebo; P=0.09). By comparison, the rate of heart failure was low in the IRIS trial (1.5%) in pioglitazone-treated participants.
There are many potential reasons for this difference in heart failure risk. First, baseline characteristics and risk factors for heart failure differed in people with previous stroke in the PROactive and IRIS trials. PROactive participants had diabetes mellitus, and HbA1c levels were higher. Baseline blood pressure was higher, as were rates of coexisting coronary disease, and baseline cardiovascular medications differed. Participants in the IRIS trial were highly selected. There was a low rate of atrial fibrillation and coexisting cardiac disease, blood pressure was well controlled, and the majority of participants had no disability after stroke. Second, it is possible that in people with stroke and no diabetes mellitus, the mechanism of incident heart failure is predominantly through the occurrence of myocardial infarction, which pioglitazone reduces, and that the mechanism of incident heart failure differs in people with diabetes mellitus. It is perhaps more important to note that the IRIS investigators followed a rigorous protocol designed to minimize heart failure risk, including dedicated weight gain, edema and breathlessness surveys, and dose reduction or cessation if concerns were noted. Twenty percent of pioglitazone-treated participants either stopped or discontinued the study drug, and pioglitazone-treated participants were less likely to be on a full dose of drug than participants treated with placebo. Typically such high attrition from a study drug would be concerning, but here it likely reflects an appropriate and rigorous approach to risk management.
The practical message from this study is clear. Pioglitazone use after stroke will not increase heart failure risk if people with diabetes mellitus, defined as having an HbA1c level of >6.5%, are not treated and if there is a rigorous approach to early identification of heart failure, weight gain, and edema followed by appropriate dose change. This is reassuring, but the potential implications are wider. The critical question is whether these data will persuade clinicians to begin to use pioglitazone in people with insulin resistance and ischemic stroke. At present, this scenario is unlikely. The main clinical concern from the IRIS trial was not heart failure but weight gain and fracture. Young and colleagues 11 correctly highlight that the benefits on cardiovascular outcomes need to be weighed against the risk of fracture and weight gain. The absolute risk of fracture in IRIS was increased by 2% and the risk of weight gain >4.5 kg by ≈20%.
There is a clear need to optimize the risk-benefit ratio for pioglitazone use after stroke. Otherwise we could miss out on the proven and clinically important benefits. The success in eliminating the excess risk of heart failure in IRIS gives cause for hope. Could the risk of fracture and weight gain be mitigated by a similarly rigorous approach to early identification and dose review? There are many potential strategies to explore, including falls risk assessment, prescribed exercise, calcium and vitamin D supplementation or bisphosphonate use, and patient selection through DEXA (dual-energy X-ray absoptiometry) scanning. Other analyses from the IRIS group demonstrate the potential for better patient selection: people with higher than median risk of stroke or myocardial infarction had an absolute risk reduction for stroke or myocardial infarction after pioglitazone of more than double that of people with lower risk. 13 These participants also had a higher risk of fracture, particularly those with aphasia or previous stroke. Other recent studies have shown that side effects from thiazolidinediones use, such as weight gain and edema, are more common in females with obesity.
14 Taken together, these findings demonstrate the potential for risk prediction algorithms to be developed to help support clinicians with the difficult decision of whether to use pioglitazone after stroke.
Understanding the implications of a large groundbreaking clinical trial often takes time. The IRIS trial, where pioglitazone gave with one hand and took with the other, is no different. However, with thoughtful analysis and further study, it finally feels like we are reaching a point where we can identify people most suitable for pioglitazone use. 
